Anti-FGD1 monoclonal antibody

Pre-made anti-FGD1 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to FGD1/FGD1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2501-Ab-1/ GM-Tg-hg-IP2501-Ab-2Anti-Human FGD1 monoclonal antibodyHuman
GM-Tg-rg-IP2501-Ab-1/ GM-Tg-rg-IP2501-Ab-2Anti-Rat FGD1 monoclonal antibodyRat
GM-Tg-mg-IP2501-Ab-1/ GM-Tg-mg-IP2501-Ab-2Anti-Mouse FGD1 monoclonal antibodyMouse
GM-Tg-cynog-IP2501-Ab-1/ GM-Tg-cynog-IP2501-Ab-2Anti-Cynomolgus/ Rhesus macaque FGD1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2501-Ab-1/ GM-Tg-felg-IP2501-Ab-2Anti-Feline FGD1 monoclonal antibodyFeline
GM-Tg-cang-IP2501-Ab-1/ GM-Tg-cang-IP2501-Ab-2Anti-Canine FGD1 monoclonal antibodyCanine
GM-Tg-bovg-IP2501-Ab-1/ GM-Tg-bovg-IP2501-Ab-2Anti-Bovine FGD1 monoclonal antibodyBovine
GM-Tg-equg-IP2501-Ab-1/ GM-Tg-equg-IP2501-Ab-2Anti-Equine FGD1 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2501-Ab-1/ GM-Tg-hg-IP2501-Ab-2; GM-Tg-rg-IP2501-Ab-1/ GM-Tg-rg-IP2501-Ab-2;
GM-Tg-mg-IP2501-Ab-1/ GM-Tg-mg-IP2501-Ab-2; GM-Tg-cynog-IP2501-Ab-1/ GM-Tg-cynog-IP2501-Ab-2;
GM-Tg-felg-IP2501-Ab-1/ GM-Tg-felg-IP2501-Ab-2; GM-Tg-cang-IP2501-Ab-1/ GM-Tg-cang-IP2501-Ab-2;
GM-Tg-bovg-IP2501-Ab-1/ GM-Tg-bovg-IP2501-Ab-2; GM-Tg-equg-IP2501-Ab-1/ GM-Tg-equg-IP2501-Ab-2
Products NameAnti-FGD1 monoclonal antibody
Formatmab
Target NameFGD1
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-FGD1 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2501-Ag-1Recombinant multi-species FGD1/ AAS/ FGDY protein


    Target information

    Target IDGM-IP2501
    Target NameFGD1
    Gene ID2245,14163,363460,701134,491901,101094403,100124501,100062071
    Gene Symbol and SynonymsAAS,FGD1,FGDY,MRXS16,ZFYVE3
    Uniprot AccessionP98174
    Uniprot Entry NameFGD1_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000102302
    Target ClassificationN/A

    The target: FGD1, gene name: FGD1, also named as AAS, FGDY, MRXS16, ZFYVE3. This gene encodes a protein that contains Dbl (DH) and pleckstrin (PH) homology domains and is similar to the Rho family of small GTP-binding proteins. The encoded protein specifically binds to the Rho family GTPase Cdc42Hs and can stimulate the GDP-GTP exchange of the isoprenylated form of Cdc42Hs. It also stimulates the mitogen activated protein kinase cascade leading to c-Jun kinase SAPK/JNK1 activation. Defects in this gene are the cause of the faciogenital dysplasia in Aarskog-Scott syndrome and a syndromatic form of X-linked cognitive disability. [provided by RefSeq, Jul 2017].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.